Brian P. Zambrowicz
Research Subjects
Brian P. Zambrowicz has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Arthur T. Sands
Lexicon Genetics, 8800 Technology Forest Place, The Woodlands, TX 77381
2 shared publicationsAlejandro Abuin
Lexicon Genetics, 8800 Technology Forest Place, The Woodlands, TX 77381
1 shared publicationAnupma Gupta
Lexicon Genetics, 8800 Technology Forest Place, The Woodlands, TX 77381
1 shared publicationArthur T Sands
Lexicon Genetics Incorporated, 8800 Technology Forest Place, The Woodlands, TX 77381, USA
1 shared publicationBillie Wayne Key
Lexicon Genetics, 8800 Technology Forest Place, The Woodlands, TX 77381
1 shared publicationBuckley Kohlhauff
Lexicon Genetics, 8800 Technology Forest Place, The Woodlands, TX 77381
1 shared publication
Latest Publications
- Open Access
- 10 November 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (24) , 14109-14114
Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention
The availability of both the mouse and human genome sequences allows for the systematic discovery of human gene function through the use of the mouse as a model system. To accelerate the genetic determination of gene function, we have developed a sequence-tagged gene-trap library of >270,000 mouse embryonic stem cell clones representing mutations in ≈60% of mammalian genes. Through the generation and phenotypic analysis of knockout mice from this resource, we are undertaking a functional screen to identify genes regulating physiological parameters such as blood pressure. As part of this screen, mice deficient for the Wnk1 kinase gene were generated and analyzed. Genetic studies in humans have shown that large intronic deletions in WNK1 lead to its overexpression and are responsible for pseudohypoaldosteronism type II, an autosomal dominant disorder characterized by hypertension, increased renal salt reabsorption, and impaired K + and H + excretion. Consistent with the human genetic studies, Wnk1 heterozygous mice displayed a significant decrease in blood pressure. Mice homozygous for the Wnk1 mutation died during embryonic development before day 13 of gestation. These results demonstrate that Wnk1 is a regulator of blood pressure critical for development and illustrate the utility of a functional screen driven by a sequence-based mutagenesis approach.
- 10 November 2003
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (24) , 14109-14114
Open AccessWnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention
The availability of both the mouse and human genome sequences allows for the systematic discovery of human gene function through the use of the mouse as a model system. To accelerate the genetic determination of gene function, we have developed a sequence-tagged gene-trap library of >270,000 mouse embryonic stem cell clones representing mutations in ≈60% of mammalian genes. Through the generation and phenotypic analysis of knockout mice from this resource, we are undertaking a functional screen to identify genes regulating physiological parameters such as blood pressure. As part of this screen, mice deficient for the Wnk1 kinase gene were generated and analyzed. Genetic studies in humans have shown that large intronic deletions in WNK1 lead to its overexpression and are responsible for pseudohypoaldosteronism type II, an autosomal dominant disorder characterized by hypertension, increased renal salt reabsorption, and impaired K + and H + excretion. Consistent with the human genetic studies, Wnk1 heterozygous mice displayed a significant decrease in blood pressure. Mice homozygous for the Wnk1 mutation died during embryonic development before day 13 of gestation. These results demonstrate that Wnk1 is a regulator of blood pressure critical for development and illustrate the utility of a functional screen driven by a sequence-based mutagenesis approach.
- 1 October 2003
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 3 (5) , 563-570
Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry
- 1 October 2003
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 3 (5) , 563-570
Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry
- Top Cited Papers
- 1 January 2003
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (1) , 38-51
Knockouts model the 100 best-selling drugs—will they model the next 100?
The biopharmaceutical industry is currently faced with a tremendous number of potential drug targets identified through the sequencing of the human genome. The challenge ahead is to delineate those targets with the greatest value for therapeutic intervention. Here, we critically evaluate mouse-knockout technology for target discovery and validation. A retrospective evaluation of the knockout phenotypes for the targets of the 100 best-selling drugs indicates that these phenotypes correlate well with known drug efficacy, illuminating a productive path forward for discovering future drug targets. Prospective mining of the druggable genome is being catalysed by large-scale mouse knockout programs combined with phenotypic screens focused on identifying targets that modulate mammalian physiology in a therapeutically relevant manner.
- 1 January 2003
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (1) , 38-51
Top Cited PapersKnockouts model the 100 best-selling drugs—will they model the next 100?
The biopharmaceutical industry is currently faced with a tremendous number of potential drug targets identified through the sequencing of the human genome. The challenge ahead is to delineate those targets with the greatest value for therapeutic intervention. Here, we critically evaluate mouse-knockout technology for target discovery and validation. A retrospective evaluation of the knockout phenotypes for the targets of the 100 best-selling drugs indicates that these phenotypes correlate well with known drug efficacy, illuminating a productive path forward for discovering future drug targets. Prospective mining of the druggable genome is being catalysed by large-scale mouse knockout programs combined with phenotypic screens focused on identifying targets that modulate mammalian physiology in a therapeutically relevant manner.
- Open Access
- 1 January 1998
- Published by EHU Press in The International Journal of Developmental Biology
- Vol. 42 (7) , 1025-1036
Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse
Gene trapping has matured into a tool with tremendous potential for mammalian biology. It both mutates and helps identify genes and can be streamlined so that many thousands of insertions can be characterized. In only a few years most of the genome of the mouse will be tagged and mutated using the latest gene trap designs. By creating such a resource, costly and time consuming alternative methods of mutagenesis and gene identification can be avoided allowing biologists to concentrate on determining gene function in vivo. This will mean a major shift in how the genome will be mined for new drug targets. Notably, gene discovery via gene traps does not suffer from the limitations of other methods as it is not biased by expression level. Mouse strains with specific gene mutations can be easily derived from a gene trap library constructed using embryonic stem cells. These strains will help determine the role of the gene product in mammalian physiology and hence the relevance of the gene product to human disease.
- 1 January 1998
- Published by EHU Press in The International Journal of Developmental Biology
- Vol. 42 (7) , 1025-1036
Open AccessComprehensive mammalian genetics: history and future prospects of gene trapping in the mouse
Gene trapping has matured into a tool with tremendous potential for mammalian biology. It both mutates and helps identify genes and can be streamlined so that many thousands of insertions can be characterized. In only a few years most of the genome of the mouse will be tagged and mutated using the latest gene trap designs. By creating such a resource, costly and time consuming alternative methods of mutagenesis and gene identification can be avoided allowing biologists to concentrate on determining gene function in vivo. This will mean a major shift in how the genome will be mined for new drug targets. Notably, gene discovery via gene traps does not suffer from the limitations of other methods as it is not biased by expression level. Mouse strains with specific gene mutations can be easily derived from a gene trap library constructed using embryonic stem cells. These strains will help determine the role of the gene product in mammalian physiology and hence the relevance of the gene product to human disease.